Autolus Therapeutics (NASDAQ:AUTL) Hits New 12-Month Low – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low on Thursday . The company traded as low as $2.29 and last traded at $2.29, with a volume of 2277337 shares. The stock had previously closed at $2.49.

Analyst Ratings Changes

AUTL has been the topic of several research analyst reports. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

The stock has a market capitalization of $609.36 million, a price-to-earnings ratio of -1.89 and a beta of 1.98. The stock has a 50 day moving average price of $3.52 and a 200-day moving average price of $3.82.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the firm earned ($0.26) EPS. As a group, research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC increased its holdings in shares of Autolus Therapeutics by 9.8% in the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after purchasing an additional 3,740 shares during the last quarter. Wealth Effects LLC grew its holdings in Autolus Therapeutics by 19.5% in the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after buying an additional 8,000 shares in the last quarter. Bellevue Group AG increased its stake in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after acquiring an additional 9,000 shares during the last quarter. State Street Corp raised its holdings in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. Finally, ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter valued at about $43,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.